Flocculated suspension of megestrol acetate
DC
First Claim
Patent Images
1. A method of treating a neoplastic condition comprising administering to a subject suffering from said condition an oral pharmaceutical composition in the form of a stable flocculated suspension in water capable of being redispersed after being allowed to settle at 40°
- C. and 75% relative humidity for a period of three months, said composition comprising;
(a) about 10 to 200 mg per ml micronized megestrol acetate;
(b) about 10 to 40% by weight of at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and
(c) about 0.0001 to 0.03% by weight of a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present in said composition.
7 Assignments
Litigations
0 Petitions
Accused Products
Abstract
A novel oral pharmaceutical composition in the form of a stable flocculated suspension in water is described as comprising: megestrol acetate; at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present.
16 Citations
1 Claim
-
1. A method of treating a neoplastic condition comprising administering to a subject suffering from said condition an oral pharmaceutical composition in the form of a stable flocculated suspension in water capable of being redispersed after being allowed to settle at 40°
- C. and 75% relative humidity for a period of three months, said composition comprising;
(a) about 10 to 200 mg per ml micronized megestrol acetate;
(b) about 10 to 40% by weight of at least one compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerol, and sorbitol; and
(c) about 0.0001 to 0.03% by weight of a surfactant, wherein polysorbate and polyethylene glycol are not simultaneously present in said composition.
- C. and 75% relative humidity for a period of three months, said composition comprising;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneePar Pharmaceutical Companies Incorporated (Endo International PLC)
-
Original AssigneePharmaceutical Resources Incorporated (Endo International PLC)
-
InventorsRagunathan, N., Femia, Robert A., Chao, James C., Ross, Malcolm S. F.
-
Primary Examiner(s)Kulkosky, Peter F.
-
Application NumberUS09/416,841Time in Patent Office658 DaysField of Search424/722US Class Current514/178CPC Class CodesA61K 9/10 Dispersions; Emulsions A61K...
